Robotic-assisted laparoscopic ureterocalicostomy (RALUC): a systematic review of its applications - Summary - MDSpire

Robotic-assisted laparoscopic ureterocalicostomy (RALUC): a systematic review of its applications

  • By

  • Theodoros Spinos

  • Panagiotis Kallidonis

  • Vasileios Tatanis

  • Kristiana Gkeka

  • Angelis Peteinaris

  • Anja Dietel

  • Ho Thi Phuc

  • Doreen Trebst

  • Stefan Siemer

  • Toni Franz

  • Evangelos Liatsikos

  • Jens-Uwe Stolzenburg

  • December 17, 2025

  • 0 min

Share

Objective:

To summarize the applications of robotic-assisted laparoscopic ureterocalicostomy (RALUC) in treating complex ureteral conditions in both adults and children.

Key Findings:
  • Eight studies met inclusion criteria, with patient numbers ranging from 4 to 24.
  • Studies included both adult and pediatric populations, with most being case-series.
  • The robotic systems used were not consistently defined across studies, affecting comparability.
Interpretation:

RALUC is emerging as a viable option for complex ureteral conditions, although the evidence base is limited and primarily consists of case-series, which may affect its generalizability.

Limitations:
  • Most studies were non-comparative and had small sample sizes, which may limit the reliability of the findings.
  • The robotic systems used were not always specified, limiting generalizability.
Conclusion:

RALUC shows promise in treating specific ureteral conditions, but further research with larger, comparative studies is needed to establish its efficacy and safety, particularly in diverse patient populations.

Original Source(s)

Robotic-assisted laparoscopic ureterocalicostomy (RALUC): a systematic review of its applications

  • by Theodoros Spinos, Panagiotis Kallidonis, Vasileios Tatanis, Kristiana Gkeka, Angelis Peteinaris, Anja Dietel, Ho Thi Phuc, Doreen Trebst, Stefan Siemer, Toni Franz, Evangelos Liatsikos, Jens-Uwe Stolzenburg

  • December 17, 2025

Related Content

A feasibility randomised controlled trial of an exergaming device aimed at improving mobility in children with cerebral palsy

Pediatric meningoencephalitis in the molecular diagnostic era: epidemiological insights from 1198 suspected cases in Germany between 2016 and 2024

Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare autosomal recessive condition that causes deficiency of the von Willebrand factor (vWF)-cleaving metalloprotease, ADAMTS13. Recombinant ADAMTS13 (rADAMTS13) is the first FDA-approved product for management of cTTP. This article reviews the pharmacology, pharmacokinetics, efficacy, safety, dosing, administration, and implications for advanced practitioners of rADAMTS13.